| Dr Jake Bergstrom, MD | |
|
17500 Se 392nd St, Auburn, WA 98092-9705 | |
| (253) 939-6648 | |
| Not Available |
| Full Name | Dr Jake Bergstrom |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 17500 Se 392nd St, Auburn, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134289051 | NPI | - | NPPES |
| 9109BE | Other | WA | REGENCE BLUE SHIELD |
| 1043009 | Medicaid | WA | |
| 1107507 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD00020595 (Washington) | Primary |
| Entity Name | Muckleshoot Indian Tribe |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558448175 PECOS PAC ID: 5092724286 Enrollment ID: O20060417000580 |
News Archive
Scientists are reporting discovery of a protein in the blood of lung cancer patients that could be used in a test for the disease - difficult to diagnose in its earliest and most treatable stages - and to develop drugs that stop lung cancer from spreading. Their study appears in ACS's Journal of Proteome Research.
Cognitive therapy, when provided by an experienced therapist, may be as effective as antidepressant medications in the initial treatment of moderate to severe major depression, according to an article in the April issue of Archives of General Psychiatry.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
The cost of low health literacy - the difference between patients' abilities to understand health information and providers' abilities to effectively communicate complex medical information - is $106 billion to $238 billion annually, according to Pfizer, a leading biopharmaceutical company. To improve the health literacy of professionals and patients, the University of Missouri will offer a health literacy study emphasis beginning this fall.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jake Bergstrom, MD Po Box 570, Oakville, WA 98568 Ph: (360) 273-5504 | Dr Jake Bergstrom, MD 17500 Se 392nd St, Auburn, WA 98092-9705 Ph: (253) 939-6648 |
News Archive
Scientists are reporting discovery of a protein in the blood of lung cancer patients that could be used in a test for the disease - difficult to diagnose in its earliest and most treatable stages - and to develop drugs that stop lung cancer from spreading. Their study appears in ACS's Journal of Proteome Research.
Cognitive therapy, when provided by an experienced therapist, may be as effective as antidepressant medications in the initial treatment of moderate to severe major depression, according to an article in the April issue of Archives of General Psychiatry.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
The cost of low health literacy - the difference between patients' abilities to understand health information and providers' abilities to effectively communicate complex medical information - is $106 billion to $238 billion annually, according to Pfizer, a leading biopharmaceutical company. To improve the health literacy of professionals and patients, the University of Missouri will offer a health literacy study emphasis beginning this fall.
› Verified 8 days ago
Eduardo Gil De Rubio, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 202 N Division St, Auburn, WA 98001 Phone: 253-833-7711 | |
Dr. Robert Todd Middleton, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 202 N Division St, Ste 201, Auburn, WA 98001 Phone: 253-939-1230 Fax: 253-735-1211 | |
Abdul R Siddiqui, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 202 N Division St Ste 301, Auburn, WA 98001 Phone: 253-288-3040 | |
Dr. Krystoff J. Godlewski, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 202 N Division St, Plaza 2 Suite 201, Auburn, WA 98001 Phone: 253-939-1230 Fax: 253-735-6479 | |
Iliana Domenica Micali, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 309 2nd St Se, Ste 100, Auburn, WA 98002 Phone: 253-333-8646 | |
Dr. James Martin Wagner, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 202 N Division St, Plaza 2 Suite 201, Auburn, WA 98001 Phone: 253-939-1230 | |
Madhavi Reddy Mandala, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 202 N Division St Ste 301, Auburn, WA 98001 Phone: 253-833-7256 |